Troglitazone decreases the proportion of small dense LDL and increases the resistance of LDL to oxidation in obese subjects

Diabetes Care

Volumn 21, Issue 5, 1998, Pages 796-799

  Tack, Cees J J ^a   Smits, Paul ^b   Demacker, Pierre N M ^a   Stalenhoef, Anton F H ^a,b  

^a RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; THIOBARBITURIC ACID REACTIVE SUBSTANCE; TROGLITAZONE;

ADULT; ARTICLE; ATHEROSCLEROSIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; CORONARY RISK; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID OXIDATION; OBESITY; RANDOMIZED CONTROLLED TRIAL; RISK MANAGEMENT;

ADULT; BLOOD GLUCOSE; BODY WEIGHT; CHOLESTEROL, LDL; CHROMANS; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FASTING; FEMALE; GLUCOSE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; LIPID PEROXIDATION; LIPIDS; MALE; OBESITY; OXIDATION-REDUCTION; THIAZOLES; THIAZOLIDINEDIONES;

EID: 0031736142     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.21.5.796     Document Type: Article

References (21)

1. Syvänne M, Taskinen M: Lipids and lipoproteins as coronary risk factors in non-insulin-dependent diabetes mellitus. Lancet 350 (Suppl. 1):20-23, 1997
2. Taskinen MR: Hyperlipidaemia in diabetes mellitus. Baillieres Clin Endocrinol Metab 4:743-75, 1990
3. Sobenin IA, Tertov VV, Orekhov AN: Atherogenic modified LDL in diabetes. Diabetes 45 (Suppl 3):S35-S39, 1997
4. Frayn KM: Insulin resistance and lipid metabolism. Curr Opin Lipidol 4:197-204, 1993
5. Suter SL, Nolan JJ, Wallace P, Gumbiner B, Olefsky JM: Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects. Diabetes Care 15:193-203, 1992
6. Nolan JJ, Ludvik B, Beerdsen P, Joyce M, Olefsky J: Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N Engl J Med 331:1188-1193, 1994
7. Saltiel AR, Olefsky JM: Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes 45:1661-1669, 1996
8. Caixàs A, Ordónez-Llanos J, de Leiva A, Playés A, Homs R, Pérez A: Optimization of glycemic control by insulin therapy decreases the proportion of small dense LDL particles in diabetic patients. Diabetes 46:1207-1213, 1997
9. Cominacini L, Garbin U, Pastorino AM, Campagnola M, Fratta Pasini A, Davoli A, Lo Cascio V: Effects of troglitazone on in vitro oxidation of LDL and HDL induced by copper ions and endothelial cells. Diabetologia 40:165-172, 1997
10. Noguchi N, Sakai H, Kato Y, Tsuchiya J, Yamamoto Y, Niki E, Horikoshi H, Kodama T: Inhibition of oxidation of LDL by troglitazone. Atherosclerosis 123:227-234, 1996
11. Demacker PNM, Hijmans AG, Vos-Janssen HE, van't Laar A, Jansen AP: A study of the use of polyethylene glycol in estimating cholesterol in high-density lipoprotein. Clin Chem 26:1775-1779, 1980
12. Lopes-Virella ME Virella G, Evans G, Malenkos SB, Colwell JA: Immunonephelometry assay of human apolipoprotein AI. Clin Chem 26:1205-1208, 1980
13. Dormans TP, Swinkels DW, de Graaf J, Hendriks JCM, Stalenhoef AFH, Demacker PNM: Single-spin density-gradient ultra-centrifugation vs. gradient gel electrophoresis: two methods for detecting low-density-lipoprotein heterogeneity compared. Clin Chem 37:853-858, 1991
14. de Rijke YB, Bredie SJH, Demacker PNM, Vogelaar JM, Hak-Lemmers HLM, Stalenhoef AFH: The redox status of coenzyme Q10 in total LDL as an indicator of in vivo oxidative modification: studies in subjects with familial combined hyperlipidemia. Arteriosder Thromb Vase Biol 17:127-133, 1997
15. de Graaf J, Hak-Lemmers HLM, Hectors MPC, Demacker PNM, Hendriks JCM, Stalenhoef AFH: Enhanced susceptibility to in vitro oxidation of the dense low density lipoprotein subfraction in healthy subjects. Arterioscler Thromb 11:298-306, 1991
16. Bergman RN, Finegood DT, Ader M: Assessment of insulin sensitivity in vivo. Endocr Rev 6:245-285, 1985
17. Ghazzi NM, Ferez JE, Antonucci TK, Driscoll JH, Huang SM, Faja BW, Whitcomb RW: Cardiac and glycemic benefits of troglitazone treatment in NIDDM: the Troglitazone Study Group. Diabetes 46:433-439, 1997
18. Chait A, Brazg RL, Tribble D, Krauss RM: Susceptibility of small dense low density lipoprotein to oxidative modification in subjects with the atherogenic lipoprotein phenotype. Am J Med 94:350-356, 1993
19. Yki-Jarvinen H: Glucose toxicity. Endocr Rev 13:415-431, 1992
20. Cominacini L, Young MMR, Capriati A, Garbin A, Fratta Pasini A, Campagnola M, Davoli A, Rigoni A, Contessi GB, Lo Cascio V: Troglitazone increases the resistance of low density lipoprotein to oxidation in healthy volunteers. Diobetologia 40:1211-1218, 1997
21. Lefebvre AM, Peinado-Onsurbe J, Leitersdorf I, Briggs MR, Paterniti JR, Fruchart JC, Fievet C, Auwerx J, Staels B: Regulation of lipoprotein metabolism by thiazolidinediones occurs through a distinct but complementary mechanism relative to fibrates. Artenoscler Thromb Vasc Biol 17:1756-1764, 1997